Clinical

Dataset Information

0

Randomized phase II study of adding steroid for prevention of venous pain in colorectal cancer patients who are receiving oxaliplatin through peripheral vein (APOLLO)


ABSTRACT: Interventions: XELOX Oxaliplatin 130mg/m2 day1 Capecitabine 2,000mg/m2 day1-14 every 3 weeks SOX Oxaliplatin 130mg/m2 day1 S-1 80-120mg/m2 day1-14 every 3 weeks Oxaliplatin is combined with dexamethasone (2 mg). XELOX Oxaliplatin 130mg/m2 day1 Capecitabine 2,000mg/m2 day1-14 every 3 weeks SOX Oxaliplatin 130mg/m2 day1 S-1 80-120mg/m2 day1-14 every 3 weeks Primary outcome(s): The incidence of venous pain:Grade>=2 Study Design: Parallel Randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2619736 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2623112 | ecrin-mdr-crc
| 2633365 | ecrin-mdr-crc
| 2620502 | ecrin-mdr-crc
| 2619574 | ecrin-mdr-crc
| 2622829 | ecrin-mdr-crc
| 2619781 | ecrin-mdr-crc
| 2626021 | ecrin-mdr-crc
| 2622964 | ecrin-mdr-crc
| 2619811 | ecrin-mdr-crc
| 2621742 | ecrin-mdr-crc